Aluminium hydroxide is commonly used to help with conditions presenting with systemic or localized discomfort. It is applied in addressing symptoms related to heightened physiological activity in the stomach, such as heartburn, sour stomach, and discomfort from peptic ulcer disease. It is applicable within clinical settings that involve acute or disruptive symptom patterns.

The medication is relevant for easing symptoms that interfere with daily comfort across conditions involving acid indigestion, upset stomach, and gastritis. In these Universal Clinical Contexts, the medication supports patients during difficult episodes by easing distress.

Aluminium hydroxide is also considered relevant for managing hyperphosphatemia (elevated phosphate levels), which is an application often used in scenarios where additional management of discomfort is required for patients with kidney disease.

“This medicine may assist with maintaining functional stability during episodes of heightened discomfort.”

Quick Fact: Relevant for Symptoms related to Physical Discomfort and Symptoms related to Systemic Imbalance

Regulatory References

1. NIH MedlinePlus Drug Information on Aluminum Hydroxide

Who Can and Cannot Use Aluminium Hydroxide?

Eligibility for Aluminium Hydroxide is determined by official regulatory bodies, focusing on patient status and specific pre-existing conditions.

Contraindications and Restrictions

Special Population Eligibility

• Pregnancy and Lactation: Use is generally advised only if the benefit outweighs the risk due to a lack of controlled data in humans. Manufacturer data on excretion into human milk is often not available.
• Age-Related Use: Use in infants and young children is generally not recommended or requires strict medical guidance. The standard adult dose population typically applies to adults and children aged 12 years and older.

Interactions with other medicines and products

Aluminium hydroxide interactions are predominantly pharmacokinetic, resulting in a reduction of other oral drug exposures due to two main mechanisms: increased gastric pH and cation binding (chelation) in the digestive tract. These interaction patterns are defined by regulatory authorities.

Documented Interaction Patterns

Administration Timing Constraints

To mitigate the pharmacokinetic interference, official regulatory labels impose Mandatory Timing Separation Rules. For many affected oral medications, including those listed above, the co-administered drug must be taken at least 2 hours before or after the dose of the aluminium-containing antacid. This required spacing is intended to ensure adequate absorption of the interacting medicine.

Population-Specific Caution

Administration with citrates is generally restricted in patients with renal impairment or those on dialysis. This combination poses a high risk of hyperaluminemia (aluminum toxicity) because the compromised kidney function prevents the effective clearance of the enhanced aluminum load.

The action of Aluminium hydroxide is entirely peripheral, occurring solely within the lumen of the gastrointestinal tract, and involves two distinct chemical mechanisms. The first is direct chemical neutralization of hydrochloric acid ( HCl), the primary acid in the stomach. The drug acts as a chemical base, consuming H^+ ions via an acid-base reaction, which rapidly increases the gastric pH. The resulting reduction of free H^+ ions decreases the local chemical irritation potential of the stomach contents. The second mechanism is non-systemic phosphate chelation. The drug acts as a chemical chelator throughout the intestine, binding to dietary phosphate ions ( HPO4^2-) to form insoluble aluminium phosphate ( AlPO4). This complex prevents phosphate absorption across the intestinal wall, leading to a net decrease in phosphate bioavailability in the body. A secondary effect involves unabsorbed aluminium compounds exerting an astringent action, altering gut motility signals and causing a physiological slowing of gut transit

Aluminium hydroxide is administered strictly via the oral route in available formulations, which include oral suspensions (liquid) and chewable tablets. For relief of high stomach acidity, dosing is typically directed multiple times per day, with administration frequently scheduled for after meals and at bedtime.

Dosing rules are formulation-dependent, with specific regimens for both single-ingredient and combination products. For symptomatic use, doses commonly range from 10 mL to 20 mL of suspension per administration. A definitive upper limit on intake is established, with the total quantity taken not to exceed the maximum dose (e.g., 60 mL to 80 mL, depending on concentration) in any 24-hour period. Furthermore, use for symptomatic relief is limited to a short duration, and the maximum dosage should not be used for more than two weeks.

Proper administration requires specific procedural steps. The liquid suspension must be shaken well before measurement, and the intake may be followed by a sip or full glass of water. If the chewable tablet form is used, it must be thoroughly chewed before swallowing. Standard practice involves the separation of administration from other oral medications by a specific interval, typically two hours, to prevent potential interference with the systemic absorption of concurrent treatments.

Aluminium Hydroxide: Recent Clinical Evidence

Aluminium hydroxide is an inorganic salt historically utilized in medicine for two primary purposes: as an antacid for managing acid-related gastrointestinal symptoms and as a phosphate binder in certain patients with kidney disease.

Efficacy as an Antacid

Clinical studies have long established the compound’s ability to neutralize gastric acid, which can provide symptomatic relief for conditions like heartburn and acid indigestion. Its effectiveness stems from a chemical reaction that increases the gastric pH to a less acidic level. Contemporary research often evaluates its performance in combination with other agents, such as magnesium hydroxide, which may be associated with improved therapeutic effect and fewer adverse gastrointestinal effects compared to using aluminium hydroxide alone.

Role as a Phosphate Binder

In patients with chronic kidney disease (CKD), aluminium hydroxide can be used to control high levels of serum phosphate (hyperphosphatemia) by forming insoluble complexes with dietary phosphate in the gut. While highly effective at binding phosphate, its use in this role has been significantly limited in long-term therapy by modern clinical guidelines. This limitation is due to the potential for aluminium accumulation in the body, which has been associated with risks like neurotoxicity, osteomalacia, and microcytic anemia, especially in individuals with impaired renal clearance. Current practice favors newer, non-aluminium-based binders for chronic management, reserving aluminium hydroxide primarily for short-term, acute hyperphosphatemia where its rapid and powerful binding capacity is needed.

Common questions about Aluminium hydroxide (FAQ)

Q: What is Aluminium hydroxide used for?

Aluminium hydroxide is primarily used as an antacid to relieve symptoms of heartburn (acid indigestion), sour stomach, and to treat the symptoms of peptic ulcers, gastritis, and esophagitis caused by excess stomach acid. It works by neutralizing the acid in the stomach.

Q: How quickly does Aluminium hydroxide start working?

As an antacid, Aluminium hydroxide works relatively quickly, often starting to neutralize stomach acid within minutes of taking it. However, the duration of its effect may vary among individuals and with the specific formulation (e.g., liquid acts faster than a tablet).

Q: What are the common side effects of Aluminium hydroxide?

The most common side effect of Aluminium hydroxide, especially when taken in larger doses or for prolonged periods, is constipation. Other common side effects can include stomach cramps or a chalky taste in the mouth.

Q: Can Aluminium hydroxide affect the absorption of other medicines?

Yes, Aluminium hydroxide can interfere with the absorption of many other medications. This is because it can bind to them in the digestive tract or change the stomach's acidity, which affects how well they are absorbed. To prevent this interaction, you should typically take Aluminium hydroxide at least 2 hours before or after taking other medicines, unless your healthcare provider gives you different instructions.

Q: How should I take Aluminium hydroxide?

• Tablets should generally be chewed thoroughly before swallowing, followed by a glass of water.
• Liquid forms should be shaken well before measuring the dose with a proper dosing cup or spoon.
• The specific dose and timing depend on your condition, so follow the instructions on the product label or your healthcare provider's advice.
• It's often recommended to take antacids after meals and at bedtime for best results.

How to Store and Dispose of Aluminium Hydroxide

Aluminium hydroxide must be stored under specific conditions to maintain its stability, as required by official regulatory labeling.

Storage Requirements

The medicine should generally be stored at 20° to 25°C (68° to 77°F), which aligns with USP Controlled Room Temperature. It is mandatory to protect the product from freezing. The container must be kept tightly closed, and for household safety, the medicine must be kept out of reach of children.

Handling and Disposal

Certain tablet forms also require protection from light and storage in a cool, dry place. Unused or expired medication must be handled and eliminated according to current local/national legislation. It is also directed to avoid spillage and not to empty the product into drains or waterways.